Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane.
Saved in:
| Title: | Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane. |
|---|---|
| Authors: | Kubeczko M; Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Cobo S; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Sanchez-Bayona R; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Pyciński B; Faculty of Biomedical Engineering, Silesian University of Technology, Zabrze, Poland., Soberino J; Breast Cancer Unit, IOB-QuirónSalud, Barcelona, Spain., Chmielik E; Tumor Pathology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Sanfeliu E; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Pathology Department, Hospital Clinic of Barcelona, Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain., Rey M; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Pardo F; Reveal Genomics, Barcelona, Spain., Aguirre A; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Castillo O; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Lesniak A; Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Oczko-Wojciechowska M; Department of Clinical and Molecular Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Carcelero E; Pharmacy Department, Hospital Clinic Barcelona, Barcelona, Spain., Adamo B; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain.; Clínic Barcelona Comprehensive Cancer Center, Barcelona, Spain., Vidal M; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain.; Clínic Barcelona Comprehensive Cancer Center, Barcelona, Spain., Bergamino M; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain.; Clínic Barcelona Comprehensive Cancer Center, Barcelona, Spain., Maues J; GRASP, GRASP, Baltimore, MD, USA., Villacampa G; Statistics Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Paré L; Reveal Genomics, Barcelona, Spain., Villagrasa P; Reveal Genomics, Barcelona, Spain., Ciruelos E; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Prat A; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain.; Reveal Genomics, Barcelona, Spain.; Clínic Barcelona Comprehensive Cancer Center, Barcelona, Spain., Jarzab M; Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Brasó-Maristany F; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. FBRASO@recerca.clinic.cat.; Reveal Genomics, Barcelona, Spain. FBRASO@recerca.clinic.cat. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2026 Feb 10; Vol. 12 (1). Date of Electronic Publication: 2026 Feb 10. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2374-4677 |
|---|---|
| DOI: | 10.1038/s41523-026-00909-0 |
